JP2002542192A - イソフラボンで臨床的な疾患を処置する方法 - Google Patents

イソフラボンで臨床的な疾患を処置する方法

Info

Publication number
JP2002542192A
JP2002542192A JP2000611910A JP2000611910A JP2002542192A JP 2002542192 A JP2002542192 A JP 2002542192A JP 2000611910 A JP2000611910 A JP 2000611910A JP 2000611910 A JP2000611910 A JP 2000611910A JP 2002542192 A JP2002542192 A JP 2002542192A
Authority
JP
Japan
Prior art keywords
diet
soy protein
isoflavone
isoflavones
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000611910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542192A5 (enExample
Inventor
ウィリアム ジェイ． バンズ，
マイケル アール． ペルソ，
トッド エイ． ウィンターズ，
マイケル エフ． シャナーン，
Original Assignee
ボード オブ トラスティース， サザン イリノイ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボード オブ トラスティース， サザン イリノイ ユニバーシティ filed Critical ボード オブ トラスティース， サザン イリノイ ユニバーシティ
Publication of JP2002542192A publication Critical patent/JP2002542192A/ja
Publication of JP2002542192A5 publication Critical patent/JP2002542192A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2000611910A 1999-04-20 2000-04-20 イソフラボンで臨床的な疾患を処置する方法 Pending JP2002542192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13015699P 1999-04-20 1999-04-20
US60/130,156 1999-04-20
PCT/US2000/010543 WO2000062774A1 (en) 1999-04-20 2000-04-20 Methods of treating clinical diseases with isoflavones

Publications (2)

Publication Number Publication Date
JP2002542192A true JP2002542192A (ja) 2002-12-10
JP2002542192A5 JP2002542192A5 (enExample) 2007-06-14

Family

ID=22443325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000611910A Pending JP2002542192A (ja) 1999-04-20 2000-04-20 イソフラボンで臨床的な疾患を処置する方法

Country Status (6)

Country Link
US (2) US6592910B1 (enExample)
EP (1) EP1171119A1 (enExample)
JP (1) JP2002542192A (enExample)
AU (1) AU777254B2 (enExample)
CA (1) CA2368784A1 (enExample)
WO (1) WO2000062774A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118314A1 (ja) * 2005-04-27 2006-11-09 Toyo Shinyaku Co., Ltd. 肝中脂質蓄積抑制剤
JP2013530181A (ja) * 2010-06-18 2013-07-25 株式会社アモーレパシフィック 有色豆抽出物を含有する組成物
JP2013534918A (ja) * 2010-06-18 2013-09-09 株式会社アモーレパシフィック 有色豆抽出物を含有する組成物
KR20150014410A (ko) * 2014-11-18 2015-02-06 경북대학교 산학협력단 페놀 화합물을 유효성분으로 포함하는 항혈전용 조성물

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US6586212B1 (en) * 1999-02-10 2003-07-01 Eastman Chemical Company Corn fiber for the production of advanced chemicals and materials: derivatizable cellulose and cellulose derivatives made therefrom
AU777254B2 (en) * 1999-04-20 2004-10-07 Board Of Trustees Of Southern Illinois University, The Methods of treating clinical diseases with isoflavones
MXPA02009956A (es) 2000-04-14 2003-02-12 Mars Inc Composiciones y metodos para mejorar la salud vascular.
AU2002308324B2 (en) * 2001-05-02 2008-04-03 Kgk Synergize Inc. Polymethoxylated flavones for treating insulin resistance
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
JP2012149096A (ja) * 2001-12-18 2012-08-09 Daicho Kikaku:Kk 抗炎症剤
AU2003228911A1 (en) * 2002-05-07 2003-11-11 Solae, Llc Low isoflavones, high saponins soy protein product and process for producing the same
US20030232068A1 (en) * 2002-06-14 2003-12-18 Lewandowski Daniel J. Food product having increased bile acid binding capacity
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
EP1545206B1 (en) 2002-07-24 2020-03-04 Children's Hospital Medical Center Compositions and products containing enantiomeric equol, and methods for their making
WO2004014886A1 (en) * 2002-08-07 2004-02-19 University Of Mississippi Antigiardial agents and use thereof
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
CN101056538A (zh) * 2004-09-27 2007-10-17 嘉吉公司 环糊精包合复合物和其制备方法
KR20080023682A (ko) * 2005-06-13 2008-03-14 카아길, 인코포레이팃드 시클로덱스트린 포접 착물 및 그의 제조 방법
WO2006137958A1 (en) * 2005-06-13 2006-12-28 Cargill Incorporated Cyclodextrin inclusion complexes and methods of preparing same
MX2008016022A (es) * 2006-06-13 2009-01-15 Cargill Inc Complejos de inclusion de ciclodextrina de particula grande y metodos para prepar los mismos.
WO2008083213A2 (en) * 2006-12-27 2008-07-10 Cargill, Incorporated Stabilisation by preparing cyclodextrin inclusion complexes
US20080283693A1 (en) * 2007-05-15 2008-11-20 Evans Michael J F Propulsion apparatus and system
US20090176871A1 (en) * 2008-01-07 2009-07-09 Schoenwetter Phillip E Treatments for Domestic Animals Having Sex Hormone Deficiencies Using Soy Germ Isoflavones
MX348902B (es) * 2011-04-20 2017-07-03 Nestec Sa Métodos y composiciones adecuados para prevenir y tratar hiperleptinemia.
US8658787B2 (en) 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
AU2013271585B2 (en) 2012-06-06 2018-02-01 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
ES2917181T3 (es) 2015-07-10 2022-07-07 Ionis Pharmaceuticals Inc Moduladores de diacilglicerol aciltransferasa 2 (DGAT2)
US20210128520A1 (en) * 2017-07-24 2021-05-06 Ke Jim Neuroprotective isoflavone compositions and methods
CN110141565A (zh) * 2019-05-10 2019-08-20 丽水市中心医院 芒柄花黄素在制备治疗肺动脉高压药物中的应用及治疗肺动脉高压药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01258669A (ja) * 1988-04-06 1989-10-16 Kikkoman Corp イソフラボン化合物の製造法
JPH09255570A (ja) * 1996-03-21 1997-09-30 Fujitsuko Kk 血中脂質濃度を低減させる薬剤及び可食性組成物
WO1997037549A1 (en) * 1996-04-10 1997-10-16 Nichimo Co., Ltd. Substance containing health-promoting component and process for the production thereof
JPH10101561A (ja) * 1996-09-27 1998-04-21 Norin Suisansyo Shikoku Nogyo Shikenjo 脂肪細胞への細胞分化促進用組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1459421A (en) * 1973-02-03 1976-12-22 British Arkady Co Ltd Production of foodstuffs from whey and soya
JPS54117034A (en) * 1978-02-28 1979-09-11 Nippon Shoji Kk Treating agent for consciousness and perception motion disorder
DE3040246C2 (de) * 1979-10-29 1985-01-10 Osaka Chemical Laboratory Co., Ltd., Osaka Sojasaponine A↓1↓ und A↓2↓ und ihre Verwendung
JPS5933232A (ja) * 1982-08-19 1984-02-23 Tokiwa Kanpou Seiyaku:Kk マメ科植物からサポニン類およびフラボン類の分離方法
US4557927A (en) * 1983-03-10 1985-12-10 Kabushiki Kaisha Hoyashibara Food products and process for producing same
JPS6269960A (ja) * 1985-09-21 1987-03-31 Kibun Kk 豆乳の製造法
AU683838B2 (en) 1992-05-19 1997-11-27 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US5885632A (en) * 1993-12-14 1999-03-23 Nichimo Co., Ltd. Process for preparing a product from a pulse crop as a starting material and a food containing the product prepared from a pulse crop as a starting material
CN1123115A (zh) * 1994-11-16 1996-05-29 邮电部干部学校威普健饮料有限公司 一种磷脂饮料及其制备方法
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
WO1998003084A1 (en) 1996-07-18 1998-01-29 Nutricor, Inc. Nutritious food preparations and methods for making them
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US5855892A (en) 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US6132795A (en) 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
DE69908809D1 (de) 1998-11-25 2003-07-17 Nutri Pharma Asa Oslo Verwendung einer zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen zur vorbeugung und/oder behandlung von lungenerkrankungen
US20030113390A1 (en) * 1998-11-25 2003-06-19 Hoie Lars Henrik Composition comprising soy protein, dietary fibers and a phytoestrogen compound and use thereof in the prevention and/or treatment of various diseases
BR9915687A (pt) 1998-11-25 2001-12-04 Nutri Pharma As Composição compreendendo proteìna de soja,fibras de dieta e um composto fitoestrogênio eseu uso na prevenção e/ou tratamento de doençascardiovasculares
DE69914947D1 (de) * 1998-11-25 2004-03-25 Nutri Pharma Asa Oslo Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von typ ii diabetes, des metabolischen syndroms und assozierten kardiovaskulären erkrankungen
US6180139B1 (en) * 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
AU777254B2 (en) * 1999-04-20 2004-10-07 Board Of Trustees Of Southern Illinois University, The Methods of treating clinical diseases with isoflavones
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1361870A2 (en) * 2001-02-01 2003-11-19 Nutri Pharma ASA A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01258669A (ja) * 1988-04-06 1989-10-16 Kikkoman Corp イソフラボン化合物の製造法
JPH09255570A (ja) * 1996-03-21 1997-09-30 Fujitsuko Kk 血中脂質濃度を低減させる薬剤及び可食性組成物
WO1997037549A1 (en) * 1996-04-10 1997-10-16 Nichimo Co., Ltd. Substance containing health-promoting component and process for the production thereof
JPH10101561A (ja) * 1996-09-27 1998-04-21 Norin Suisansyo Shikoku Nogyo Shikenjo 脂肪細胞への細胞分化促進用組成物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118314A1 (ja) * 2005-04-27 2006-11-09 Toyo Shinyaku Co., Ltd. 肝中脂質蓄積抑制剤
JP2013530181A (ja) * 2010-06-18 2013-07-25 株式会社アモーレパシフィック 有色豆抽出物を含有する組成物
JP2013534918A (ja) * 2010-06-18 2013-09-09 株式会社アモーレパシフィック 有色豆抽出物を含有する組成物
KR20150014410A (ko) * 2014-11-18 2015-02-06 경북대학교 산학협력단 페놀 화합물을 유효성분으로 포함하는 항혈전용 조성물
KR102010505B1 (ko) 2014-11-18 2019-08-14 경북대학교 산학협력단 페놀 화합물을 유효성분으로 포함하는 항혈전용 조성물

Also Published As

Publication number Publication date
AU777254B2 (en) 2004-10-07
WO2000062774A1 (en) 2000-10-26
US20030180404A1 (en) 2003-09-25
US6592910B1 (en) 2003-07-15
AU4471300A (en) 2000-11-02
EP1171119A1 (en) 2002-01-16
CA2368784A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
JP2002542192A (ja) イソフラボンで臨床的な疾患を処置する方法
US6572876B2 (en) Administering a composition containing plant sterol, soy protein and isoflavone for reducing LDL-cholesterol
US5855892A (en) Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5952374A (en) Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
Rieckhoff et al. Effects of different cereal fibers on cholesterol and bile acid metabolism in the Syrian golden hamster
JP2002530346A (ja) 大豆蛋白質、食物繊維およびフィトエストロゲン化合物を含む組成物、および肺疾患の予防および／または治療におけるその使用
US7090863B2 (en) Hypocholesterolemic composition and methods of use
US7285297B1 (en) Method of reducing low density liproprotein cholesterol concentration
US20060154855A1 (en) Methods and compositions for beta conglycinin fraction of soy protein
Matsuo Plasma cholesterol reduction by defatted soy ontjom (fermented with Neurospora intermedia) in rats fed a cholesterol-free diet
AU783820B2 (en) Composition for and method of reducing low density lipoprotein cholesterol concentration
AU779014B2 (en) Composition for and method of reducing low density lipoprotein cholesterol concentration
MXPA98003404A (en) The use of a daidzein material in the preparation of compositions to reduce the concentration of cholesterol ldl and to increase the concentration of cholesterol hdl in the blood to reduce the risk of aterosclerosis and vascu disease
Lee et al. BETA-CONGLYCININ DEFICIENT IN SOY ISOFLAVONES AND SOYASAPONINS DID NOT LOWER PLASMA CONCENTRATIONS OF LIPOPROTEINS AND CHOLESTEROL OVER TIME IN MILDLY HYPERCHOLESTEROLEMIC WOMEN
MXPA01005134A (en) Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110426